"Ondansetron" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Descriptor ID |
D017294
|
| MeSH Number(s) |
D03.383.129.308.690 D03.633.100.473.144.500 D03.633.300.148.500
|
| Concept/Terms |
Ondansetron Hydrochloride- Ondansetron Hydrochloride
- Hydrochloride, Ondansetron
- Ondansetron Monohydrochloride
- Monohydrochloride, Ondansetron
- Ondansetron Monohydrochloride Dihydrate
- Dihydrate, Ondansetron Monohydrochloride
- Monohydrochloride Dihydrate, Ondansetron
|
Below are MeSH descriptors whose meaning is more general than "Ondansetron".
Below are MeSH descriptors whose meaning is more specific than "Ondansetron".
This graph shows the total number of publications written about "Ondansetron" by people in this website by year, and whether "Ondansetron" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 3 | 0 | 3 |
| 1995 | 2 | 0 | 2 |
| 1996 | 1 | 0 | 1 |
| 1997 | 3 | 0 | 3 |
| 1998 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 1 | 2 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2010 | 2 | 0 | 2 |
| 2016 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ondansetron" by people in Profiles.
-
Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review. Expert Opin Drug Saf. 2020 Feb; 19(2):205-210.
-
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy. Eur J Cancer. 2016 Apr; 57:23-30.
-
Clinical evaluation of two antiemetic combinations palonosetron dexamethasone versus ondansetron dexamethasone in chemotherapy of head and neck cancer. Singapore Med J. 2010 Nov; 51(11):871-5.
-
Prospective trial of efficacy and safety of ondansetron and fluoxetine in patients with obstructive sleep apnea syndrome. Sleep. 2010 Jul; 33(7):982-9.
-
The effect of premedication with OTFC, with or without ondansetron, on postoperative agitation, and nausea and vomiting in pediatric ambulatory patients. Paediatr Anaesth. 2004 Sep; 14(9):759-67.
-
Methylnaltrexone prevents morphine-induced kaolin intake in the rat. Life Sci. 2004 Apr 16; 74(22):2685-91.
-
Serotonin-3 receptors in the actions of alcohol, alcohol reinforcement, and alcoholism. Alcohol Clin Exp Res. 2004 Feb; 28(2):257-67.
-
Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists. Ann Pharmacother. 2003 Sep; 37(9):1276-86.
-
The prevention of emesis in plastic surgery: a randomized, prospective study. Plast Reconstr Surg. 2002 Jun; 109(7):2487-94.
-
Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer. 2002 Jun 01; 94(11):3032-41.